Most interestingly, CD49a was frequently co‐expressed with CD69 and CD103, and in vivo blockade of CD49a or CD103 in a C57BL/6 melanoma mouse model significantly impaired control of subcutaneous B16‐OVA tumors, supporting the notion of TRM cell‐mediated anti‐tumor immunity. Here, CD69 is linked to neoplasm.